Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OPK 
Opko Health Inc (OPK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: OPK (1-star) is a SELL. SELL since 1 days. Profits (2.47%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -41.79% | Avg. Invested days 38 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.14B USD | Price to earnings Ratio - | 1Y Target Price 3.99 |
Price to earnings Ratio - | 1Y Target Price 3.99 | ||
Volume (30-day avg) 6735986 | Beta 1.71 | 52 Weeks Range 1.15 - 2.04 | Updated Date 04/1/2025 |
52 Weeks Range 1.15 - 2.04 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -7.46% | Operating Margin (TTM) -18.05% |
Management Effectiveness
Return on Assets (TTM) -8.12% | Return on Equity (TTM) -3.86% |
Valuation
Trailing PE - | Forward PE 64.52 | Enterprise Value 1214143459 | Price to Sales(TTM) 1.6 |
Enterprise Value 1214143459 | Price to Sales(TTM) 1.6 | ||
Enterprise Value to Revenue 1.7 | Enterprise Value to EBITDA 8.98 | Shares Outstanding 671550016 | Shares Floating 253987028 |
Shares Outstanding 671550016 | Shares Floating 253987028 | ||
Percent Insiders 59.26 | Percent Institutions 29.91 |
Analyst Ratings
Rating 4.33 | Target Price 3.96 | Buy 4 | Strong Buy 2 |
Buy 4 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Opko Health Inc
Company Overview
History and Background
Opko Health Inc. was founded in 1991 as IVAX Corporation, which later merged with Teva Pharmaceutical Industries in 2006. The company was later renamed Opko Health Inc. and has focused on diagnostics, pharmaceuticals, and medical devices.
Core Business Areas
- Pharmaceuticals: Focuses on developing and commercializing pharmaceutical products, including Rayaldee for secondary hyperparathyroidism.
- Diagnostics: Develops and commercializes diagnostic tests, including 4Kscore test for prostate cancer risk.
- Medical Devices: Involved in the research and development of medical devices.
Leadership and Structure
Dr. Phillip Frost serves as the Chairman and CEO. The company has a typical corporate structure with various executive vice presidents overseeing different business segments.
Top Products and Market Share
Key Offerings
- Rayaldee: Rayaldee is a treatment for secondary hyperparathyroidism (SHPT) in adults with chronic kidney disease (CKD). While specific market share data is difficult to obtain, its competitors include calcimimetics like Sensipar (Amgen) and other Vitamin D analogs. The most recent report indicates approximately $120 Million Revenue.
- 4Kscore Test: The 4Kscore test is a blood test used to assess the risk of aggressive prostate cancer. The competitors include Prostate Health Index (PHI) and PCA3 tests. Market Share is relatively small.
Market Dynamics
Industry Overview
The healthcare industry is characterized by constant innovation, regulatory scrutiny, and significant competition. It is driven by aging populations, increasing prevalence of chronic diseases, and advancements in technology.
Positioning
Opko Health Inc. occupies a niche position with its focus on diagnostics and niche pharmaceutical products. Its competitive advantage is its 4Kscore test and Rayaldee product, although it faces competition from larger pharmaceutical companies.
Total Addressable Market (TAM)
The TAM for prostate cancer diagnostics and secondary hyperparathyroidism treatments is estimated to be in the billions of dollars. Opko is positioned to capture a small, but growing, percentage of this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary diagnostic tests (e.g., 4Kscore)
- Established pharmaceutical product (Rayaldee)
- Experienced leadership
- Strategic acquisitions
Weaknesses
- Reliance on key products
- History of losses and negative cash flow
- High debt levels
- Litigation risks
- Regulatory hurdles
Opportunities
- Expansion of diagnostic testing services
- Development of new pharmaceutical products
- Strategic partnerships
- Market growth in key therapeutic areas
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes impacting drug pricing
- Patent expirations
- Economic downturn affecting healthcare spending
- Clinical trial failures
Competitors and Market Share
Key Competitors
- AMGN
- HOLX
- PRGO
Competitive Landscape
Opko faces significant competition from larger, more established companies in the pharmaceutical and diagnostics industries. Its competitive advantage lies in its innovative products, but it needs to improve its financial performance to compete effectively.
Major Acquisitions
Bio-Reference Laboratories
- Year: 2015
- Acquisition Price (USD millions): 1470
- Strategic Rationale: Expanded OPKO's diagnostics business significantly, providing a platform for growth in laboratory testing services.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent due to product development challenges and market competition.
Future Projections: Analyst estimates vary widely, reflecting uncertainty about the company's future prospects and regulatory hurdles.
Recent Initiatives: Recent initiatives include focusing on growing sales of Rayaldee and expanding the availability of the 4Kscore test.
Summary
Opko Health is a company with promising diagnostic and pharmaceutical assets but faces significant financial challenges. While the 4Kscore test and Rayaldee offer growth potential, the company's high debt levels and history of losses are concerning. Opko needs to improve its profitability and demonstrate consistent growth to gain investor confidence and navigate competitive threats.
Similar Companies
- AMGN
- HOLX
- PRGO
- BRLI
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Third-Party Market Research
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Opko Health Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 1995-11-02 | Chairman & CEO Dr. Phillip Frost Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2997 | Website https://www.opko.com |
Full time employees 2997 | Website https://www.opko.com | ||
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.